442 related articles for article (PubMed ID: 23549880)
21. Loss of p57 expression and RhoA overexpression are associated with poor survival of patients with hepatocellular carcinoma.
Hu T; Guo H; Wang W; Yu S; Han L; Jiang L; Ma J; Yang C; Guo Q; Nan K
Oncol Rep; 2013 Oct; 30(4):1707-14. PubMed ID: 23842948
[TBL] [Abstract][Full Text] [Related]
22. Clinical and pathological significance of myeloid differentiation factor 88 expression in human hepatocellular carcinoma tissues.
Kinowaki K; Soejima Y; Kumagai A; Kondo F; Sano K; Fujii T; Kitagawa M; Fukusato T
Pathol Int; 2017 May; 67(5):256-263. PubMed ID: 28370778
[TBL] [Abstract][Full Text] [Related]
23. Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition.
Hou KZ; Fu ZQ; Gong H
World J Gastroenterol; 2015 Jan; 21(2):475-83. PubMed ID: 25593462
[TBL] [Abstract][Full Text] [Related]
24. ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway.
Chen H; Wang H; Yu X; Zhou S; Zhang Y; Wang Z; Huang S; Wang Z
BMC Cancer; 2020 Sep; 20(1):853. PubMed ID: 32891122
[TBL] [Abstract][Full Text] [Related]
25. High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma.
He C; Xu J; Zhang J; Xie D; Ye H; Xiao Z; Cai M; Xu K; Zeng Y; Li H; Wang J
Hum Pathol; 2012 Sep; 43(9):1425-35. PubMed ID: 22406368
[TBL] [Abstract][Full Text] [Related]
26. Expression of claudins-1, -4, -5, -7 and occludin in hepatocellular carcinoma and their relation with classic clinicopathological features and patients' survival.
Bouchagier KA; Assimakopoulos SF; Karavias DD; Maroulis I; Tzelepi V; Kalofonos H; Karavias DD; Kardamakis D; Scopa CD; Tsamandas AC
In Vivo; 2014; 28(3):315-26. PubMed ID: 24815833
[TBL] [Abstract][Full Text] [Related]
27. Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival.
Nakai S; Masaki T; Shiratori Y; Ohgi T; Morishita A; Kurokohchi K; Watanabe S; Kuriyama S
Int J Oncol; 2002 Apr; 20(4):769-75. PubMed ID: 11894123
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-224 upregulation and AKT activation synergistically predict poor prognosis in patients with hepatocellular carcinoma.
Yu L; Zhang J; Guo X; Li Z; Zhang P
Cancer Epidemiol; 2014 Aug; 38(4):408-13. PubMed ID: 24923856
[TBL] [Abstract][Full Text] [Related]
29. CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery.
Yang XR; Xu Y; Yu B; Zhou J; Li JC; Qiu SJ; Shi YH; Wang XY; Dai Z; Shi GM; Wu B; Wu LM; Yang GH; Zhang BH; Qin WX; Fan J
Clin Cancer Res; 2009 Sep; 15(17):5518-27. PubMed ID: 19706825
[TBL] [Abstract][Full Text] [Related]
30. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma.
Yao DF; Wu XH; Zhu Y; Shi GS; Dong ZZ; Yao DB; Wu W; Qiu LW; Meng XY
Hepatobiliary Pancreat Dis Int; 2005 May; 4(2):220-6. PubMed ID: 15908319
[TBL] [Abstract][Full Text] [Related]
31. CC chemokine receptor 6 expression predicts poor prognosis in hepatocellular carcinoma.
Liu F; Lv H; Jia X; Liu G; Li T; Xu Z; Li J
J Surg Oncol; 2014 Aug; 110(2):151-5. PubMed ID: 24634224
[TBL] [Abstract][Full Text] [Related]
32. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma.
Sun BS; Dong QZ; Ye QH; Sun HJ; Jia HL; Zhu XQ; Liu DY; Chen J; Xue Q; Zhou HJ; Ren N; Qin LX
Hepatology; 2008 Dec; 48(6):1834-42. PubMed ID: 18972404
[TBL] [Abstract][Full Text] [Related]
33. Increased expression of MyD88 and association with paclitaxel resistance in breast cancer.
Xiang F; Ni Z; Zhan Y; Kong Q; Xu J; Jiang J; Wu R; Kang X
Tumour Biol; 2016 May; 37(5):6017-25. PubMed ID: 26596839
[TBL] [Abstract][Full Text] [Related]
34. The prognostic value of combined TGF-β1 and ELF in hepatocellular carcinoma.
Ji F; Fu SJ; Shen SL; Zhang LJ; Cao QH; Li SQ; Peng BG; Liang LJ; Hua YP
BMC Cancer; 2015 Mar; 15():116. PubMed ID: 25880619
[TBL] [Abstract][Full Text] [Related]
35. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma.
Ke AW; Shi GM; Zhou J; Wu FZ; Ding ZB; Hu MY; Xu Y; Song ZJ; Wang ZJ; Wu JC; Bai DS; Li JC; Liu KD; Fan J
Hepatology; 2009 Feb; 49(2):491-503. PubMed ID: 19065669
[TBL] [Abstract][Full Text] [Related]
36. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
[TBL] [Abstract][Full Text] [Related]
37. Expression of matrix metalloproteinase-9 in predicting prognosis of hepatocellular carcinoma after liver transplantation.
Nart D; Yaman B; Yilmaz F; Zeytunlu M; Karasu Z; Kiliç M
Liver Transpl; 2010 May; 16(5):621-30. PubMed ID: 20440771
[TBL] [Abstract][Full Text] [Related]
38. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling.
Zhou SL; Zhou ZJ; Hu ZQ; Li X; Huang XW; Wang Z; Fan J; Dai Z; Zhou J
Cancer Lett; 2015 Mar; 358(2):124-135. PubMed ID: 25462858
[TBL] [Abstract][Full Text] [Related]
39. Reduced expression of transcriptional intermediary factor 1 gamma promotes metastasis and indicates poor prognosis of hepatocellular carcinoma.
Ding ZY; Jin GN; Wang W; Chen WX; Wu YH; Ai X; Chen L; Zhang WG; Liang HF; Laurence A; Zhang MZ; Datta PK; Zhang B; Chen XP
Hepatology; 2014 Nov; 60(5):1620-36. PubMed ID: 24954480
[TBL] [Abstract][Full Text] [Related]
40. [Expression characteristics of nuclear factor kappa B in hepatocellular carcinoma tissues].
Zhou WM; Ping JL; Qian FC; Zhang GL
Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):843-6. PubMed ID: 19958645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
